Cryosite featured by The Armchair Analyst

The Armchair Analyst - one of Australia's leading ASX life-sciences newsletters - published an in-depth piece on Cryosite. To read the full article, click here.

Here are some of the highlights.

On what makes a great storage business:

Most people misunderstand the storage industry. They think the product is space. It's not. The product is reliability

Great storage businesses don't retain customers. They trap value.

On visiting the Cryosite facility:

As soon as you walk into the Cryosite facility, all the TGA licences are on the wall. This is Cryosite's moat. It's about a 3-5 year lead time to get a new licence and a $20 million facility buildout.

When the product in your freezer is literally irreplaceable... being 'reliable' is no longer a nice-to-have, and it is the entire value proposition.

On the growth tailwind:

The ultra-frozen segment grew 58% in FY25, driven by cell and gene therapy. The CAR-T market alone is heading toward US$4.8 billion in 2026 and is tipped to roughly double by 2031, with Asia-Pacific the fastest-growing slice. Every one of those therapies needs a cold chain.

On where Cryosite sits today:

Cryosite at 5 cents in 2019 was its own hole in the ground. A broken little cord-blood company that had just been fined by the regulator. Today, it's over a dollar, with a moat, a second site, and a tailwind it didn't have to build.

Read the full article: https://thearmchairanalyst.com/p/shelf-control-the-cryosite-story-asx-cte